newsfilter
← Latest News
GlobeNewswire·

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London

  • Corvus Pharmaceuticals (Nasdaq: CRVS) announced its leadership team will attend the 2026 Jefferies Global Healthcare Conference in London.
  • The corporate overview presentation is scheduled for Monday, November 16, 2026, at 2:30 PM GMT (9:30 am ET / 6:30 am PT).
  • A live webcast of the presentation will be available for 90 days via the investor relations section of the Corvus website.
  • Corvus is a clinical-stage biopharmaceutical company developing ITK inhibition as a new immunotherapy approach for immune diseases & cancer.
  • Lead candidate soquelitinib, an investigational oral small molecule, is in a Phase 3 trial for relapsed/refractory peripheral T cell lymphoma.
  • Soquelitinib is also being evaluated in a Phase 2 trial for atopic dermatitis & a Phase 1b trial for hidradenitis suppurativa.
  • Additional clinical-stage candidates are being developed for various cancer indications.
Company
Corvus Pharmaceuticals, Inc.
Keywords
Nasdaq:CRVS, Corvus Pharmaceuticals, Inc., Corvus Pharmaceuticals, ITK inhibition, soquelitinib